Company to discuss financial results for the quarter ending June 30, 2013
and the collaboration agreement with Bayer HealthCare announced today
Tel Aviv, Israel, August 5, 2013 — Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 7, 2013 to review both second quarter 2013 results and the collaboration agreement announced today with Bayer HealthCare. The second quarter financial statements were filed with the SEC on Form 6-K after the close of business on Friday, August 2 and are available on the Company’s website (www.cgen.com), as is today’s press release regarding the collaboration with Bayer HealthCare. In addition, copies of both the financial statements and today’s press release can be obtained by return email by contacting IR@cgen.com.
To access the conference call, please dial 1-888-407-2553 from the US, or + 972-3-9180610 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-295-2634 from the US or +972-3-925-5939 internationally. The replay will be available through August 10, 2013.
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company’s business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen’s corporate website at www.cgen.com.
Global Media Liaison